This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Innate Immunity Stimulation Via TLR9 in Early AD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05606341
Recruitment Status : Recruiting
First Posted : November 4, 2022
Last Update Posted : March 12, 2024
Sponsor:
Collaborator:
Alzheimer's Association
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13 subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs. placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8 weeks. The primary objective will be to assess safety and tolerability of CpG 1018.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Alzheimer Dementia Drug: CpG1018 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Subjects will be randomly allocated in a blinded fashion to receive s.c. injection of either CpG ODN (dose level 1, 0.1 mg/kg) or placebo (saline). Dose escalation will occur after 10 weeks after the last injection in a new subject cohort, and will be based on the safety data and immunostimulatory assessments at previous dose level cohorts.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1 Clinical Trial of Innate Immunity Stimulation Via TLR9 in Early Alzheimer's Disease (AD)
Actual Study Start Date : March 13, 2023
Estimated Primary Completion Date : November 2025
Estimated Study Completion Date : November 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CpG 1018 0.1 mg/kg

3 injections at Day 1, Week 4, and Week 8.

Treatment administered as morning injection of dose 0.1mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.

Drug: CpG1018

0.1 mg/kg dose administered via subcutaneous injection.

TLR9 agonist supplied by Dynavax Technologies Inc.


Experimental: CpG 1018 0.25 mg/kg

3 injections at Day 1, Week 4, and Week 8.

Treatment administered as morning injection of dose 0.25 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.

Drug: CpG1018

0.25 mg/kg dose administered via subcutaneous injection.

TLR9 agonist supplied by Dynavax Technologies Inc.


Experimental: CpG 1018 0.5 mg/kg

3 injections at Day 1, Week 4, and Week 8.

Treatment administered as morning injection of dose 0.5 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.

Drug: CpG1018

0.5 mg/kg dose administered via subcutaneous injection.

TLR9 agonist supplied by Dynavax Technologies Inc.


Placebo Comparator: Placebo
3 injections of sterile saline at Day 1, Week 4, and Week 8, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.
Drug: Placebo
Sterile saline injection supplied by the NYU Investigational Pharmacy.




Primary Outcome Measures :
  1. Number of Patient-Reported Adverse Events (AEs) [ Time Frame: Up to Week 18 ]
    AEs defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.

  2. Percentage of Participants with Rheumatoid Factor (RF) Confirmed by Autoimmunity Marker Screening Test Result [ Time Frame: Up to Week 18 ]
    Evaluation of RF in patient blood samples at Baseline, Day 56, Week 14 and Week 18.

  3. Percentage of Participants with Antinuclear Antibody (ANA) Confirmed by Autoimmunity Marker Screening Test Result [ Time Frame: Up to Week 18 ]
    Evaluation of ANA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.

  4. Percentage of Participants with Antineutrophil Cytoplasmic Antibody (ANCA) Confirmed by Autoimmunity Marker Screening Test Result [ Time Frame: Up to Week 18 ]
    Evaluation of ANCA in patient blood samples at Baseline, Day 56, Week 14 and Week 18.

  5. Percentage of Participants with Amyloid-Related Imaging Abnormalities-Haemosiderin (ARIA-H) Confirmed by Magnetic Resonance Imaging (MRI) [ Time Frame: Up to Week 14 ]
    Evaluation of ARIA-H at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.

  6. Percentage of Participants with Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI) [ Time Frame: Up to Week 14 ]
    Evaluation of ARIA-E at Baseline and Week 14 using 3T PET/MR Siemens Biograph system.


Secondary Outcome Measures :
  1. Change in AD Assessment Scale Cognitive Subscale (ADAS-Cog-13) Scores [ Time Frame: Baseline, Week 18 ]
    13-item self-assessment measuring levels of cognitive and non-cognitive dysfunctions from mild to severe. Total scores range from 0 to 85. Lower scores indicate greater cognitive performance. A decrease in scores indicates cognitive performance improved during the observational period.

  2. Change in AD Cooperative Study-Activities of Daily Living Inventory, Mild Cognitive Impairment version (ADCS-ADL-MCI) Scores [ Time Frame: Baseline, Week 18 ]
    18-item questionnaire measuring a participant's basic and instrumental activities of daily living over the previous month. Total scores range from 0-53, where higher scores indicate greater competence in performing activities. An increase in scores indicates competence increased during the observational period.

  3. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores [ Time Frame: Baseline, Week 18 ]
    C-SSRS systematically tracks suicidal ideation and behavior. The total score range is 0 (no ideation is present) to 5 (active suicidal ideation with specific plan and intent). A decrease in scores indicates suicidal ideation and behavior decreased during the observational period.

  4. Change in Global Clinical Dementia Rating (CDR-Global) [ Time Frame: Baseline, Week 18 ]
    5-point questionnaire assessing six domains of cognitive and functional performance applicable to Alzheimer's disease and related dementias: Memory, Orientation; Judgement & Problem Solving; Community Affairs; Home & Hobbies; and Personal Care. Higher scores indicate greater severity of dementia: 0= Normal, 0.5=very mild dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia.

  5. Change in Montreal Cognitive Assessment (MoCa) Score [ Time Frame: Baseline, Week 18 ]
    30-item assessment of global cognitive function. Total scores range from 0 to 30, with higher scores indicating greater cognitive function. Scores of 26 and higher are consider to be normal. An increase in scores indicates cognitive function increased during the observational period.

  6. Change in Plasma Amyloid Biomarker Concentration [ Time Frame: Baseline, Week 18 ]
    Amyloid biomarker concentration detected via plasma analysis.

  7. Change in Cerebral Spinal Fluid (CSF) Amyloid Biomarker Concentration [ Time Frame: Baseline, Week 18 ]
    Amyloid biomarker concentration detected via CSF analysis.

  8. Change in Plasma Tau Biomarker Concentration [ Time Frame: Baseline, Week 18 ]
    Tau biomarker concentration detected via plasma analysis.

  9. Change in CSF Tau Biomarker Concentration [ Time Frame: Baseline, Week 18 ]
    Tau biomarker concentration detected via CSF analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 65-85 years of age
  2. MCI due to AD or mild AD dementia per NIA-AA specified criteria published in 2018
  3. Montreal Cognitive Assessment (MoCA) score ≥17 AND;
  4. Positive Florbetaben PET amyloid scan, or other positive PET amyloid scan performed within one year of study enrollment
  5. Must be able to provide consent or assent (If applicable).
  6. Must be willing and able to participate in all study related procedures.
  7. Must have a reliable study partner to provide information on the subject's cognitive and functional status. Study partner must have sufficient contact with the subject, as determined by the PI, and be available to accompany the subject to clinic visits or by phone.

Exclusion Criteria:

  1. History of psychiatric illness (e.g. hallucinations, major depression, suicidal ideation or delusions) that could interfere with completion of study related procedures as determined by PI
  2. History of autoimmune disorders or antibody-mediated disease, severe asthma, or other serious infection or systemic illness, as determined by PI
  3. Use of corticosteroids or immunosuppressive drugs within 30 days of study entry
  4. History of splenectomy
  5. Renal impairment
  6. Use of chloroquine within 8 weeks of study entry
  7. Inability to undergo MRI imaging
  8. History of TIA, stroke or seizures within 12 months of screening
  9. Any neurological condition other than AD that could contribute to cognitive impairment (including related to possible "long COVID") as determined by PI
  10. Participation in any other current AD investigational interventional trial
  11. Current use of an anti-coagulant
  12. Current use of drugs that are major substrates of cytochrome P450 (CYP) enzyme 1A2
  13. Recent exposure to COVID-19 infection within 14 days or recent onset of symptoms within 14 days that may be related to COVID-19 infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05606341


Contacts
Layout table for location contacts
Contact: Alok Vedvyas 212-263-2048 Alok.Vedvyas@nyulangone.org

Locations
Layout table for location information
United States, New York
NYU Langone Health Recruiting
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Alzheimer's Association
Investigators
Layout table for investigator information
Principal Investigator: Arjun Masurkar, MD NYU Langone Medical Center
Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT05606341    
Other Study ID Numbers: 20-00267
First Posted: November 4, 2022    Key Record Dates
Last Update Posted: March 12, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Alok.Vedvyas@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Alok.Vedvyas@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Tauopathies
Neurodegenerative Diseases
1018 oligonucleotide
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs